Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AJU-C52H vs Coadministration of C52R1M and C52R2 in Healthy Adults
NCT05077462Phase 1Unknown
- Sponsor
- AJU PHARM Co., Ltd.
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of amlodipine + chlorthalidone + valsartan in hypertension (HTN) (2 arms), sponsored by AJU PHARM Co., Ltd. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Status: unknown.
02
Drugs
amlodipine + chlorthalidone + valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05077462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077462.